Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 412
of 21Next
1:

Molecular response to aromatase inhibitor treatment in primary breast cancer.

Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M.

Breast Cancer Res. 2007;9(3):R37.

PMID: 17555561 [PubMed - indexed for MEDLINE]

2:

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.

Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM.

Pharmacogenet Genomics. 2007 Oct;17(10):813-26.

PMID: 17885619 [PubMed - indexed for MEDLINE]

3:

Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.

Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S.

Mol Cancer Res. 2005 Apr;3(4):203-18.

PMID: 15831674 [PubMed - indexed for MEDLINE]

4:

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID: 16706574 [PubMed - indexed for MEDLINE]

5:

Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.

Miller WR, Stuart M, Sahmoud T, Dixon JM.

Br J Cancer. 2002 Oct 21;87(9):950-5.

PMID: 12434282 [PubMed - indexed for MEDLINE]

6:

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

PMID: 17610808 [PubMed - indexed for MEDLINE]

7:

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Gibson LJ, Dawson CK, Lawrence DH, Bliss JM.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review.

PMID: 17253488 [PubMed - indexed for MEDLINE]

8:

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC.

Lancet Oncol. 2005 Jun;6(6):383-91. Erratum in: Lancet Oncol. 2005 Jun;6(6):357.

PMID: 15925816 [PubMed - indexed for MEDLINE]

9:

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.

PMID: 17919537 [PubMed - indexed for MEDLINE]

10:

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.

Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, Veronesi P, D'Alessandro C, Luini A, Dellapasqua S, Viale G, Goldhirsch A, Colleoni M.

Br J Cancer. 2007 Sep 17;97(6):802-8. Epub 2007 Aug 21.

PMID: 17712311 [PubMed - indexed for MEDLINE]

11:

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.

J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2.

PMID: 17200148 [PubMed - indexed for MEDLINE]

12:

Aromatase inhibitors: cellular and molecular effects.

Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):83-9.

PMID: 16002280 [PubMed - indexed for MEDLINE]

13:

Primary hormone treatment in postmenopausal women with breast cancer.

Maciá Escalante S, Pons Sanz V, Rodríguez Lescure A, Ballester Navarro I, Carrato Mena A.

Clin Transl Oncol. 2006 May;8(5):372-4.

PMID: 16760014 [PubMed - indexed for MEDLINE]

14:

The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.

Forbes JF.

Semin Oncol. 2006 Apr;33(2 Suppl 7):S2-7.

PMID: 16730270 [PubMed - indexed for MEDLINE]

15:

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.

Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP.

Gynecol Oncol. 2007 Sep;106(3):461-8. Epub 2007 Jul 10.

PMID: 17624412 [PubMed - indexed for MEDLINE]

16:

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE.

J Clin Oncol. 2002 Feb 1;20(3):751-7.

PMID: 11821457 [PubMed - indexed for MEDLINE]

17:

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.

Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM.

Cancer. 2007 Jul 15;110(2):244-54.

PMID: 17538978 [PubMed - indexed for MEDLINE]

18:

Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.

Miller WR, Larionov A, Anderson TJ, Walker JR, Krause A, Evans DB, Dixon JM.

Cancer. 2008 Feb 1;112(3 Suppl):689-94.

PMID: 18072233 [PubMed - indexed for MEDLINE]

19:

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.

Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R.

Eur J Cancer. 2003 Nov;39(16):2318-27.

PMID: 14556923 [PubMed - indexed for MEDLINE]

20:

The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.

Monnier AM.

Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.

PMID: 17492927 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 412
of 21Next